Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Prometheus Laboratories Announces Multiple Presentations on Precision-Guided Dosing and Monitoring at the Digestive Disease Week 2021 Annual Meeting

2 oral presentations and 5 posters on effectiveness of Prometheus' precision-guided lab services to improve therapeutic intervention for treatment of IBD

Prometheus Laboratories Logo

News provided by

Prometheus Laboratories, Inc.

May 11, 2021, 15:25 ET

Share this article

Share toX

Share this article

Share toX

SAN DIEGO, May 11, 2021 /PRNewswire/ -- Prometheus Laboratories, Inc. ("Prometheus"), a leader of precision healthcare, announced today multiple presentations and posters on precision-guided dosing and monitoring of Inflammatory Bowel Disease (IBD) at the virtual 2021 Digestive Disease Week (DDW) meeting, being held May 21-23. Along with clinical collaborators, Prometheus will present two oral presentations, one during a plenary session; and five posters, two named as Posters of Distinction. 

"The data presented at DDW this year represents our commitment to advancing precision-guided clinical testing to optimize individual treatment outcomes," commented Dr. Thierry Dervieux, Chief Scientific Officer. "It also underscores the value of our unparalleled biorepository and database in contributing to the development and validation of novel diagnostic solutions to improve patient outcomes."

The data presented at DDW will include:

  • A model-informed precision dosing tool for adalimumab which was developed and evaluated utilizing Prometheus Anser® testing on a clinical cohort of 7,755 IBD patients. Results point to the potential use of such a model to help improve dose optimization; and
  • Results from a study evaluating the combination of serum infliximab levels and an endoscopic healing index score with two Prometheus services, Anser and Monitr™, in patients with Crohn's Disease (CD) to guide dose optimization. The data indicates the potential to allow clinicians to distinguish pharmacokinetic from pharmacodynamic failure, and thus guide therapeutic decision-making in patients with CD.

Presentations and posters highlighting data from Prometheus Lab at DDW 2021 are below:

Abstract

Title

Date/Time/Session

Oral Presentation



Plenary session
780

HOST SEROREACTIVITY TO MICROBIAL
ANTIGENS IS ASSOCIATED WITH FUTURE
ONSET OF CROHN'S DISEASE INDEPENDENT
OF GUT BARRIER FUNCTION, SUBCLINICAL
INFLAMMATION, AND GENETIC RISK

Sunday, May 23, 2021 from 3:30 PM to 5:00 PM EDT
Immunology, Microbiology & Inflammatory
Bowel Diseases (IMIBD) Section
Distinguished Abstract Plenary

Lecture Presentation
854

RISK OF IMMUNOGENICITY TO A SUBSEQUENT
THERAPY IS THE HIGHEST DURING THE FIRST
YEAR AFTER A SWITCH IN THERAPY IN
IMMUNOGENIC PATIENTS WITH
INFLAMMATORY BOWEL DISEASE

Sunday, May 23, 2021 from 5:30 PM to
7:00 PM EDT
Biologic and Disease Monitoring in IBD

Posters



Poster of Distinction
Su432

IMPACT OF THIOPURINE EXPOSURE ON
IMMUNOGENICITY TO INFLIXIMAB IS
NEGLIGIBLE IN THE SETTING OF ELEVATED
INFLIXIMAB CONCENTRATIONS

Sunday, May 23, 2021 from 12:15 PM to
1:00 PM EDT
Therapeutic Monitoring

Poster of Distinction
Su457

DOES PREOPERATIVE SERUM USTEKINUMAB
CONCENTRATION PREDICT THIRTY-DAY
POSTOPERATIVE OUTCOMES IN PATIENTS
WITH INFLAMMATORY BOWEL DISEASE
UNDERGOING ABDOMINAL SURGERY?

Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDT
Immunology‚ Microbiology & Inflammatory Bowel Diseases: IBD: Uncontrolled Therapeutic Observations in Humans Biologic

Su444

MODEL INFORMED PRECISION DOSING OF ADALIMUMAB BY INDIVIDUALIZED PHARMACOKINETICS IN A LARGE COHORT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASES

Sunday, May 23, 2021 from 12:15 PM to
1:00 PM EDT
Therapeutic Monitoring

Su469

TUMOR NECROSIS FACTOR IMPACTS INFLIXIMAB CLEARANCE IN INFLAMMATORY BOWEL DISEASES

Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDT
Uncontrolled Therapeutic Observations in Humans Biologic

Su439

THE VALUE OF COMBINED SERUM INFLIXIMAB AND ENDOSCOPIC HEALING INDEX MONITORING FOR GUIDING INFLIXIMAB DOSING IN PATIENTS WITH CROHN'S DISEASE

Sunday, May 23, 2021 from 12:15 PM to 1:00 PM EDT
Therapeutic Monitoring

The complete abstracts can be found on the DDW 2021 website.

About Prometheus Laboratories
Prometheus Laboratories is a specialty clinical laboratory, which enables precision-guided care in Inflammatory Bowel Disease and other GI disorders. We discover, develop and commercialize testing services that help clinicians improve outcomes across the patient journey, from disease interception and stratification, to therapy selection, optimization and monitoring. For more information, please visit https://www.prometheuslabs.com, visit our virtual booth at DDW 2021, or engage with us on LinkedIn.

About Anser
Anser testing uniquely measures serum drug (infliximab or infliximab biosimilars, adalimumab, ustekinumab, vedolizumab) and antidrug antibody levels using a proprietary, drug tolerant, homogenous mobility shift assay technology. Anser testing aids in the assessment and optimization of biologic therapy management decisions.

About Monitr
Monitr is a first-of-its-kind, non-invasive, multi-protein serum biomarker test developed and validated to assess endoscopic disease activity in patients with CD. The test aids in distinguishing CD patients in endoscopic remission from those with active disease, providing an endoscopic healing index for objective evaluation of mucosal healing.

Investor and Media Contact
Amy Conrad
Juniper Point
(858) 914-1962
[email protected]

SOURCE Prometheus Laboratories, Inc.

Related Links

https://www.prometheuslabs.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.